Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.475
-0.065 (-4.22%)
At close: Apr 28, 2026, 4:00 PM EDT
1.560
+0.085 (5.76%)
After-hours: Apr 28, 2026, 7:28 PM EDT
Company Description
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases.
Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Chemomab Therapeutics Ltd.
| Country | Israel |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Adi George |
Contact Details
Address: Building C, 10th Floor Tel Aviv-Yafo, 6158101 Israel | |
| Phone | 972 77 331 0156 |
| Website | chemomab.com |
Stock Details
| Ticker Symbol | CMMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534248 |
| CUSIP Number | 16385C203 |
| ISIN Number | US16385C2035 |
| Employer ID | 81-3676773 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, Chief Executive Officer and Executive Director |
| Sigal Fattal CPA, M.B.A. | Chief Financial Officer |
| Jack Lawler | Chief Development Officer |
| Dr. David M. Weiner M.B.A., M.D. | Interim Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | 6-K | Report of foreign issuer |
| Mar 23, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 20, 2026 | 6-K | Report of foreign issuer |
| Mar 19, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 10, 2026 | SCHEDULE 13G/A | Filing |
| Nov 21, 2025 | 6-K | Report of foreign issuer |
| Aug 22, 2025 | 6-K | Report of foreign issuer |
| Aug 14, 2025 | 6-K | Report of foreign issuer |
| Aug 11, 2025 | SCHEDULE 13G/A | Filing |